Michael Thomas Henderson Sells 20,000 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The stock was sold at an average price of $63.35, for a total value of $1,267,000.00. Following the transaction, the chief executive officer owned 1,172,987 shares of the company’s stock, valued at $74,308,726.45. This trade represents a 1.68% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, January 14th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $81.11, for a total value of $1,622,200.00.
• On Wednesday, December 10th, Michael Thomas Henderson sold 20,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $75.38, for a total transaction of $1,507,600.00.
• On Thursday, December 4th, Michael Thomas Henderson sold 40,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $75.01, for a total transaction of $3,000,400.00.

Apogee Therapeutics Trading Down 2.2%

Apogee Therapeutics stock opened at $67.78 on Friday. Apogee Therapeutics Inc. has a 52 week low of $26.20 and a 52 week high of $84.56. The stock has a market cap of $4.63 billion, a price-to-earnings ratio of -15.47 and a beta of 1.42. The company’s 50-day moving average price is $74.39 and its two-hundred day moving average price is $57.36.

Institutional Trading of Apogee Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC raised its holdings in shares of Apogee Therapeutics by 2.2% during the fourth quarter. Commonwealth Equity Services LLC now owns 7,151 shares of the company’s stock valued at $540,000 after acquiring an additional 152 shares during the period. Stifel Financial Corp grew its position in Apogee Therapeutics by 3.5% during the 4th quarter. Stifel Financial Corp now owns 5,214 shares of the company’s stock worth $394,000 after purchasing an additional 175 shares in the last quarter. ANTIPODES PARTNERS Ltd raised its stake in Apogee Therapeutics by 41.2% during the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 843 shares of the company’s stock valued at $33,000 after purchasing an additional 246 shares during the period. Comerica Bank lifted its holdings in shares of Apogee Therapeutics by 1.0% in the fourth quarter. Comerica Bank now owns 35,872 shares of the company’s stock valued at $2,708,000 after purchasing an additional 338 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Apogee Therapeutics by 99.2% in the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $33,000 after buying an additional 383 shares during the period. 79.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on APGE shares. UBS Group raised Apogee Therapeutics to a “strong-buy” rating in a research note on Wednesday, January 7th. Stifel Nicolaus set a $133.00 target price on Apogee Therapeutics in a report on Tuesday, January 6th. Wolfe Research initiated coverage on shares of Apogee Therapeutics in a research report on Wednesday, January 7th. They issued a “peer perform” rating on the stock. Stephens initiated coverage on shares of Apogee Therapeutics in a research report on Tuesday, December 16th. They set an “overweight” rating and a $95.00 price objective for the company. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $116.00 price objective on shares of Apogee Therapeutics in a research note on Wednesday, January 7th. Three investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Apogee Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $104.58.

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.